ACROBIOSYSTEMS CO.,LTD. — Investor Relations & Filings
ACROBIOSYSTEMS CO.,LTD. is a global biotechnology company specializing in the development and manufacturing of high-quality recombinant proteins and critical reagents for the life sciences industry. The company provides a comprehensive portfolio of products designed to accelerate the development of target therapeutics, including antibodies, cell and gene therapies, and vaccines. Key offerings include a wide range of biotinylated proteins, enzymes, and assay kits characterized by high bioactivity and batch-to-batch consistency. ACROBIOSYSTEMS supports drug discovery and clinical development through specialized platforms for protein engineering and characterization. Its products serve a diverse client base of pharmaceutical companies, biotechnology firms, and academic research institutions worldwide, focusing on therapeutic areas such as oncology, immunology, and infectious diseases.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 2025年度内部控制评价报告 | 2026-04-20 | Chinese | |
| 关于部分募投项目结项并将节余募集资金永久补充流动资金及注销相关募集资金专户的公告 | 2026-04-20 | Chinese | |
| 2025年度独立董事述职报告（张勇） | 2026-04-20 | Chinese | |
| 2026年一季度报告 | 2026-04-20 | Chinese | |
| 容诚会计师事务所关于北京百普赛斯生物科技股份有限公司募集资金年度存放与使用鉴证报告 | 2026-04-20 | Chinese | |
| 招商证券股份有限公司关于北京百普赛斯生物科技股份有限公司使用部分暂时闲置募集资金和自有资金进行现金管理的核查意见 | 2026-04-20 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
12 filings
| |||||
| 44581864 | 2025年度内部控制评价报告 | 2026-04-20 | Chinese | ||
| 44581863 | 关于部分募投项目结项并将节余募集资金永久补充流动资金及注销相关募集资金专户的公告 | 2026-04-20 | Chinese | ||
| 44581861 | 2025年度独立董事述职报告（张勇） | 2026-04-20 | Chinese | ||
| 44581851 | 2026年一季度报告 | 2026-04-20 | Chinese | ||
| 44581847 | 容诚会计师事务所关于北京百普赛斯生物科技股份有限公司募集资金年度存放与使用鉴证报告 | 2026-04-20 | Chinese | ||
| 44581844 | 招商证券股份有限公司关于北京百普赛斯生物科技股份有限公司使用部分暂时闲置募集资金和自有资金进行现金管理的核查意见 | 2026-04-20 | Chinese | ||
| 44581841 | 关于使用部分暂时闲置募集资金和自有资金进行现金管理的公告 | 2026-04-20 | Chinese | ||
| 44581839 | 关于与专业投资机构共同投资的公告 | 2026-01-29 | Chinese | ||
| 44581828 | 2025年度业绩预告 | 2026-01-29 | Chinese | ||
| 44581825 | 关于向香港联交所递交境外上市股份(H股)发行上市申请并刊发申请资料的公告 | 2026-01-27 | Chinese | ||
| 44581823 | 上海市通力律师事务所关于北京百普赛斯生物科技股份有限公司2026年第一次临时股东会的法律意见书 | 2026-01-06 | Chinese | ||
| 44581797 | 2026年第一次临时股东会决议公告 | 2026-01-06 | Chinese | ||
|
2025
3 filings
| |||||
| 44581790 | 股东会议事规则（草案） | 2025-12-18 | Chinese | ||
| 44581771 | 信息披露管理制度（草案） | 2025-12-18 | Chinese | ||
| 44581760 | 董事会议事规则（草案） | 2025-12-18 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Soiken Holdings Inc.
Commercializes medical research via biomarker tech, clinica…
|
2385 | JP | Professional, scientific and te… |
|
Solid Biosciences Inc.
Develops gene therapies for rare neuromuscular and cardiac …
|
SLDB | US | Professional, scientific and te… |
|
Sona Nanotech Inc.
Develops and supplies proprietary gold nanorod technology f…
|
SONA | CA | Professional, scientific and te… |
|
SPARC TECHNOLOGIES LIMITED
Develops graphene technologies, green hydrogen, and sodium-…
|
SPN | AU | Professional, scientific and te… |
|
SpectraCure
Develops a minimally invasive treatment system for internal…
|
SPEC | SE | Professional, scientific and te… |
|
Sprint Bioscience
Develops and out-licenses preclinical oncology drug candida…
|
SPRINT | SE | Professional, scientific and te… |
|
SPRUCE BIOSCIENCES, INC.
A clinical-stage biopharma developing therapies for underse…
|
SPRB | US | Professional, scientific and te… |
|
SpyGlass Pharma, Inc.
Ophthalmic biotech developing drug delivery integrated with…
|
SGP | US | Professional, scientific and te… |
|
SQI Diagnostics Inc.
Precision medicine biotech developing innovative diagnostic…
|
SQD.H | CA | Professional, scientific and te… |
|
STARPHARMA HOLDINGS LIMITED
Develops dendrimer technology for pharmaceutical and life s…
|
SPL | AU | Professional, scientific and te… |
ACROBIOSYSTEMS CO.,LTD. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/56034/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=56034 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=56034 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=56034 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 56034}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for ACROBIOSYSTEMS CO.,LTD. (id: 56034)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.